1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc.

CPIX
Cumberland Pharmaceuticals Inc.US flagNASDAQ Global Select
6.58
USD
+0.21
- -
98.59MMarket Cap

Total Valuation

Cumberland Pharmaceuticals Inc. carries a market capitalization of 98.59M, placing it among publicly traded companies globally. Its enterprise value stands at 47.35M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap98.59M
Enterprise Value47.35M

Share Statistics

Cumberland Pharmaceuticals Inc. currently has 14.98M shares outstanding.

Shares Outstanding14.98M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 1.16, and the price-to-book ratio stands at 2.25.

PE RatioN/A
PS Ratio1.16
PB Ratio2.25
P/TBV Ratio6.40
P/FCF Ratio123.30
P/OCF Ratio34.21

Enterprise Valuation

On an enterprise value basis, Cumberland Pharmaceuticals Inc. trades at an EV/EBITDA multiple of 55.52 and an EV/FCF ratio of 58.12.

EV / Sales1.13
EV / EBITDA55.52
EV / EBITN/A
EV / FCF58.12

Financial Position

Cumberland Pharmaceuticals Inc. maintains a current ratio of 0.95, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 47.27, indicating elevated leverage, while an interest coverage ratio of -4.03 demonstrates limited ability to service its debt obligations.

Current Ratio0.95
Quick Ratio0.73
Debt / Equity47.27
Debt / EBITDA-5.98
Interest Coverage-4.03

Financial Efficiency

Return on Equity (ROE)-29.36
Return on Assets (ROA)-10.48
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.50

Taxes

Income Tax38,457.00
Effective Tax RateN/A

Stock Price Statistics

Cumberland Pharmaceuticals Inc.'s stock has gained approximately 116.44737% over the past 52 weeks. The 50-day moving average sits at 5.34, while the 200-day moving average is 3.85.

Beta (5Y)N/A
52-Week Price Change116.44737%
50-Day Moving Average5.34
200-Day Moving Average3.85
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Cumberland Pharmaceuticals Inc. generated 41.94M in revenue and converted that into -7.38M in net income, yielding earnings per share of -0.49. EBITDA reached -1.68M, while operating income came in at -7.21M.

Revenue41.94M
Gross Profit34.76M
Operating Income-7.21M
Pretax Income-7.20M
Net Income-7.38M
EBITDA-1.68M
EBIT-7.21M
Earnings Per Share (EPS)-0.49

Balance Sheet

Cumberland Pharmaceuticals Inc. holds 11.01M in cash and equivalents against 10.07M in total debt, resulting in a net debt position of -5.77M. Total book value stands at 21.64M, with working capital of -1.70M providing operational flexibility.

Cash & Cash Equivalents11.01M
Total Debt10.07M
Net Debt-5.77M
Equity (Book Value)21.64M
Book Value Per Share1.45
Working Capital-1.70M

Cash Flow

Cumberland Pharmaceuticals Inc. produced 1.42M in operating cash flow over the past twelve months. After subtracting 1.03M in capital expenditures, free cash flow totaled 2.45M - equivalent to 0.16 per share.

Operating Cash Flow1.42M
Capital Expenditures1.03M
Free Cash Flow2.45M
FCF Per Share0.16

Margins

Cumberland Pharmaceuticals Inc. operates with a gross margin of 82.89, reflecting its pricing power and cost economics. The operating margin of -17.20 and net profit margin of -17.60 provide insight into operational efficiency.

Gross Margin82.89
Operating Margin-17.20
Pretax Margin-17.17
Profit Margin-17.60
EBITDA Margin-4.01

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield4.08
FCF Yield0.81

Scores

Cumberland Pharmaceuticals Inc. posts an Altman Z-Score of 0.13, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score0.13